Press releases

18 September, 2023

Abliva to Participate in World Mitochondrial Disease Week 2023

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company will participate in W ...

4 September, 2023

Abliva’s Lead Candidate KL1333 Receives FDA Fast Track Designation

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the company’s lead candidate KL133 ...

18 August, 2023

Regulatory

Abliva AB Interim Report January – June 2023

The first patient was dosed in the FALCON study ⎮ Orphan Drug Designation for NV354

29 June, 2023

Abliva presents at UMDF Mitochondrial Medicine 2023

28 June, 2023

Abliva announces first patient dosed in the FALCON study

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the first patient has been dosed ...

12 June, 2023

Abliva presents scientific data at international conference on mitochondrial medicine

23 May, 2023

Regulatory

Abliva AB Interim Report January – March 2023

Patient screening ongoing in the FALCON study | Orphan Drug Designation for NV354

5 May, 2023

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ) on May 5, 2023

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 5, 2023, held its Annual General Meeting (“AGM”). A summary of the resolution follows.

4 May, 2023

Regulatory

Amendment of the Nomination Committee’s proposal for Abliva’s Annual General Meeting in 2023

The notice for Abliva’s Annual General Meeting (AGM) 2023 was announced in a press release on April 4th, 2023. The Nominating Committee's proposal for the election of Board members was […] ...

17 April, 2023

Abliva’s Drug Candidate NV354 Granted Orphan Drug Designation for the Treatment of Mitochondrial Disease

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the drug candidate NV354 has ...

4 April, 2023

Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting, held at 10 a.m. on Friday, 5 May 2023 at Medicon Village, Scheeletorget ...

31 March, 2023

Regulatory

Abliva AB Publishes 2022 Annual Report

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced that the English version ...